NEW YORK-June 26, 2017-Accenture has developed and introduced a new analytics platform to provide real-time insights on the status and performance of clinical trials for the life sciences industry. The platform, known as the Clinical Operations Insights Platform (COIP), is a module of the Accenture Life Sciences Cloud for R&D, an industry platform for running clinical trials for better patient outcomes.
Accenture has joined forces with the Metrics Champion Consortium (MCC) in the development of COIP, using MCC’s industry clinical trial metrics to measure a company’s clinical trial performance. MCC is an open, collaborative organization devoted to the development of standardized metrics to improve clinical trials.
The platform allows life sciences clinical operations managers to manage clinical trial programs from anywhere, anytime, by consolidating into a single analytics platform internal and external data sources across clinical trial management systems, electronic data capture systems, and clinical research organization partners.
“We are excited about our collaboration with MCC and the addition of their clinical operations performance metrics into our Clinical Operations Insights Platform module,” said Kevin Julian, who leads Accenture’s Life Sciences practice in North America. “Together we are integrating technology with metrics standards, making it easier for our clients to understand the health of their study portfolio, manage their business more effectively and bring their treatments to patients.”
MCC has also joined the Accenture Life Sciences Cloud Coalition, which includes Eli Lilly, GSK, Merck, Pfizer, and other pharmaceutical companies. As a member of the coalition, MCC will provide input on the use of standardized performance metrics in the Accenture Life Sciences Cloud for R&D. The aim of the Accenture Life Sciences Cloud Coalition is to enable the R&D function, speed up the drug development process while improving quality and cost for the industry.
“We are pleased to build MCC’s standardized metrics into the Accenture Life Sciences Cloud for R&D Clinical Operations Insights Platform and to welcome Accenture as a member of our consortium”, said Linda Sullivan, co-founder and president of MCC. “Our members are looking for innovative ways to implement and effectively utilize the standardized metric sets and tools developed in our collaborative working groups – having access to MCC standardized performance metrics in the Accenture Life Sciences Cloud for R&D platform is a win-win for current and future users.”
Contacts:
Teresa Holland
Metrics Champion Consortium
+ 1 317 622 0266 ext. 108
tholland@metricschampion.org
Cam Granstra
Accenture
+1 312 693 5992
cameria.l.granstra@accenture.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.